Literature DB >> 17094456

Synergism between apple procyanidins and lysosomotropic drugs: potential in chemoprevention.

Nikolaus Seiler1, Mehdi Chaabi, Stamatiki Roussi, Francine Gossé, Annelise Lobstein, Francis Raul.   

Abstract

BACKGROUND: Procyanidins are apple constituents with potential in colon cancer chemoprevention.
MATERIALS AND METHODS: Human colon cancer derived metastatic cells (SW620), growing under standardized conditions, were exposed to procyanidins and lysosomotropic compounds. Growth, apoptosis and lysosomal integrity was determined using published methods.
RESULTS: Lysosomotropic drugs (MDL 72527, phenylalanine methylester and chloroquine) amplified procyanidin-induced growth inhibition and apoptosis in SW620 cells at non-cytotoxic concentrations. The improved toxicity of the drug combinations relies primarily on the enhancement of lysosomal membrane permeability.
CONCLUSION: Combinations with non-toxic concentrations of lysosomotropic compounds improve the anti-carcinogenic properties of apple procyanidins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17094456

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Procyanidin b2 cytotoxicity to mcf-7 human breast adenocarcinoma cells.

Authors:  Monalisa M Avelar; Cibele M C P Gouvêa
Journal:  Indian J Pharm Sci       Date:  2012-07       Impact factor: 0.975

2.  Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells.

Authors:  Yao Wang; Rui-Qing Peng; Dan-Dan Li; Ya Ding; Xiao-Qi Wu; Yi-Xin Zeng; Xiao-Feng Zhu; Xiao-Shi Zhang
Journal:  Chin J Cancer       Date:  2011-10

3.  Cytotoxic and Antitumor Activity of Lactaptin in Combination with Autophagy Inducers and Inhibitors.

Authors:  Anastasia V Bagamanshina; Olga S Troitskaya; Anna A Nushtaeva; Anastasia Yu Yunusova; Marina O Starykovych; Elena V Kuligina; Yuri Ya Kit; Max Richter; Fabian Wohlfromm; Thilo Kähne; Inna N Lavrik; Vladimir A Richter; Olga A Koval
Journal:  Biomed Res Int       Date:  2019-06-17       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.